Diabetes In Sindhi Families In Nagpur (DISFIN) (DISFIN)
Diabetes In Sindhi Families In Nagpur (DISFIN): An Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
At each Participant Recruitment Center:
- We announced the dates of recruitment locally through pamphlet distribution, personal conversations, emails and a study website to the residents of the study areas. When the participants came in for the study, they were first administered the informed consent form.
- Upon receiving such consent a Field Research Officer (FRO) appointed specifically for the study collected the demographic data and conduct anthropometric measurements. All the data has been directly input into a cloud-based database through tablet computers made available to the FROs for the purpose of the study.
- A trained nurse then measured the blood pressure of the participant as follows: These measurements were conducted using a random-zero sphygmomanometer on the left arm. To account for the potential variability in the blood pressure measurements, we measured the blood pressure thrice with 5-minute intervals but use the average of the last two readings as the phenotypic trait value. Appearance of the first Korotkov sound and disappearance of the fifth Korotkov sound was considered as the systolic and diastolic blood pressures, respectively.
- Thereafter the participant were under electrocardiographic evaluation. The examination was conducted by a trained ECG technician using a portable ECG machine with limb leads, chest leads and augmented leads. The signal recordings were digitized and stored as digital signal files. Novacode software was used to quantitatively measure important phenotypic traits from the ECG signals.
- The participant then proceeded to measurement of random blood glucose using a glucometer and disposable test strip. The results are shared with the participant as well as entered directly into the cloud-based database.
- Then the participant were given a urine sample collection cup. The urine sample was used to estimate urine sugar and microalbuminuria.
- The participant were then given an appointment for fasting blood studies.
- On the day of the appointment, a trained laboratory technician appointed for the purpose of the study drew 10 ml of venous blood from the ante-cubital vein. This blood sample will be used for lipid profile studies (total and free serum cholesterol, serum triglycerides, high-density lipoproteins, low-density lipoproteins, very low-density lipoproteins and apolipoproteins), fasting plasma glucose, serum cotinine (to corroborate the history of smoking), serum creatinine (to quantify urinary dilution), serum C peptide (to distinguish between type 1 and type 2 diabetes), plasma insulin and serum HbA1c (glycated hemoglobin).
- To maximize participation for the fasting blood studies, we sent text reminders to participants before the date of appointment. If the participant cannot make it on the day of appointment then we again sent text and/or telephonic reminders to them for a revised appointment date. We did this for a total of three times before the reminders can be stopped.
- If the participants were diagnosed with any medical condition during the examination then they were duly referred to expert medical help outside of the DISFIN study. If the participant was newly diagnosed as a case of T2D during study the participant was referred to expert diabetologist in the city for further medical care.
- Lastly, we provided a nominal time compensation for each participant who completed all the study procedures.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Nagpur, Maharashtra, India, 440022
- Lata Medical Research Foundation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Resident of Jaripatka or Khamla areas of Nagpur
- Self-reported Sindhi
- Age ≥20 years
- Has given informed consent
Exclusion Criteria:
- Pregnant or lactating woman
- Known type 1 diabetes
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Type 2 diabetes
Time Frame: March 1, 2016 - Feb 28, 2017
|
Presence of T2D will be defined as: Self-report or FPG ≥126 mg/dl or currently receiving antidiabetic drugs or HbA1c ≥6.5% or random blood sugar ≥ 200 mg/dl
|
March 1, 2016 - Feb 28, 2017
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin resistance
Time Frame: March 1, 2016 - Feb 28, 2017
|
Insulin resistance will be measured using the Homeostatic Model of Assessment-Insulin resistance (HOMA_IR)
|
March 1, 2016 - Feb 28, 2017
|
|
Hypertension
Time Frame: March 1, 2016 - Feb 28, 2017
|
Hypertension will be defined using the 2017 revised criteria (systolic blood pressure >120 mmHg and/or diastolic blood pressure >80 mmHg)
|
March 1, 2016 - Feb 28, 2017
|
|
Obesity
Time Frame: March 1, 2016 - Feb 28, 2017
|
Obesity will be defined as body mass index (BMI) exceeding 30 Kg/m2.
BMI will be calculated as weight (in Kg)/Height2 (in meters).
|
March 1, 2016 - Feb 28, 2017
|
|
Central obesity
Time Frame: March 1, 2016 - Feb 28, 2017
|
Central obesity will be defined using population-specific cut off for waist circumference.
For Asian Indians, the cutoffs are: male (>=90cm) and female (>=80 cm).
|
March 1, 2016 - Feb 28, 2017
|
|
Dyslipidemia
Time Frame: March 1, 2016 - Feb 28, 2017
|
We will use the definition of dyslipidemia as described by the International Diabetes Federation (IDF).
The criteria use dyslipidemia is a composite outcomes based on measured values of serum triglycerides (≥ 150 mg/dLmg/dl) and high density lipoprotein (HDL) cholesterol (< 40 mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 mmol/L) in females).
Additionally, total serum cholesterol (≥200 mg/dl) will also be considered as dyslipidemia.
|
March 1, 2016 - Feb 28, 2017
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Manju R Mamtani, MD, Treasurer
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RPC#23A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.